NovoCure Ltd

038

Company Profile

  • Business description

    NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

  • Contact

    Grenville Street
    No. 4 The Forum, Second Floor
    St. HelierJE2 4UF
    JEY

    T: +44 1534756700

    E: [email protected]

    https://www.novocure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    1,605

Stocks News & Analysis

stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.
stocks

Turnaround progressing for ASX share

Margins have rebased by shares are undervalued.
stocks

Investors overlooking ASX share’s potential

International expansion is a distraction from valuable local business.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,735.4083.10-0.94%
CAC 407,987.490.000.00%
DAX 4024,307.92357.351.49%
Dow JONES (US)49,686.12159.950.32%
FTSE 10010,323.75128.381.26%
HKSE25,675.18287.55-1.11%
NASDAQ26,090.73134.41-0.51%
Nikkei 22560,815.95593.34-0.97%
NZX 50 Index12,845.4182.490.65%
S&P 5007,403.055.45-0.07%
S&P/ASX 2008,505.3072.60-0.85%
SSE Composite Index4,131.533.86-0.09%

Market Movers